Gielen RCAM, Poncet C, van 't Veer LJ, Rubio IT, et al. 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. Eur J Cancer 2026;247:117044.
PMID: 42762561